Pulling SEC filings + quote and writing the call…

PHIBRO ANIMAL HEALTH CORP
Next earnings Aug 25, 2026 (after close) · consensus $0.73 EPS, $389M rev
Last earnings +4.0% on 2026-05-06
Revenue grew 27.4% YoY.
Middling fundamentals offset by an attractive price (~33% below fair value) — worth a look on the value angle.
Sources: SEC EDGAR (CIK 0001069899, latest 10-Q filed 2026-05-06) · EODHD · as of 6/27/2026, 3:08:10 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
PHIBRO ANIMAL HEALTH CORP shows $1.30B in FY2025 revenue (+27.4% YoY), a 3.7% net margin, and 16.9% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $833M | $942M | $978M | $1.02B | $1.30B |
| Gross profit | $271M | $285M | $298M | $313M | $400M |
| Operating income | $74.9M | $79.0M | $71.8M | $53.3M | $110M |
| Net income | $54.4M | $49.2M | $32.6M | $2.42M | $48.3M |
| Diluted EPS | $1.34 | $1.21 | $0.81 | $0.06 | $1.19 |
| Net margin | 6.5% | 5.2% | 3.3% | 0.2% | 3.7% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1047 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Last 90 days: 1 open-market buy · 30 sales
| 2026-05-29 | CORCORAN E THOMAS Director | Buy | 10.0K @ $31.77 | $318K |
| 2026-05-07 | BENDHEIM JACK President and CEO | Sell | 1.35K @ $47.59 | $64.2K |
| 2026-05-07 | BENDHEIM JACK President and CEO | Sell | 1.15K @ $48.31 | $55.5K |
| 2026-05-07 | BENDHEIM JACK President and CEO | Sell | 2.03K @ $49.19 | $99.8K |
| 2026-05-06 | BENDHEIM JACK President and CEO | Sell | 5.63K @ $57.18 | $322K |
| 2026-05-06 | BENDHEIM JACK President and CEO | Sell | 1.41K @ $58.13 | $81.7K |
| 2026-05-05 | BENDHEIM JACK President and CEO | Sell | 6.26K @ $55.73 | $349K |
| 2026-05-05 | BENDHEIM JACK President and CEO | Sell | 776.00 @ $56.37 | $43.7K |
| 2026-04-30 | BENDHEIM JACK President and CEO | Sell | 5.80K @ $52.65 | $306K |
| 2026-04-30 | BENDHEIM JACK President and CEO | Sell | 1.24K @ $53.32 | $65.8K |
| 2026-04-29 | BENDHEIM JACK President and CEO | Sell | 4.00K @ $52.70 | $211K |
| 2026-04-29 | BENDHEIM JACK President and CEO | Sell | 3.04K @ $53.21 | $162K |